Application of medication therapy management-based “in-hospital assessment - home-based intervention” pharmaceutical care in patients with depression

Table 1 Comparison of baseline characteristics and medication-related problem risk stratification between two groups of patients with depression

Characteristic	Intervention group (n = 52)	Control group (n = 52)	t/χ2 value	P value
Demographic characteristics
Age, years	45.20 ± 8.70	46.50 ± 9.30	0.762	0.447
Female	32 (61.54)	30 (57.69)	0.155	0.694
Clinical characteristics
HAMD-17 score	24.60 ± 3.90	24.30 ± 3.60	0.421	0.674
Disease duration, months	18.40 ± 6.20	19.10 ± 7.00	0.582	0.561
First-episode depression	28 (53.85)	25 (48.08)	0.336	0.562
Two or more comorbid chronic diseases	15 (28.85)	13 (25.00)	0.195	0.659
MRP risk stratification (STOPP/START criteria)
High risk, ≥ 3 MRPs	22 (42.31)	20 (38.46)	0.155	0.694
Medium risk, 1-2 MRPs	25 (48.08)	26 (50.00)	0.032	0.858
Low risk, no MRPs	5 (9.62)	6 (11.54)	0.109	0.741

Data are presented as mean ± SD or n (%).

HAMD-17: 17-item Hamilton Depression Rating Scale; STOPP/START: Screening Tool of Older Persons’ Prescriptions/Screening Tool to Alert doctors to Right Treatment; MRPs: Medication-related problems.